¸é¿ª°ü¹®¾ïÁ¦Á¦ ½ÃÀå º¸°í¼­ : À¯Çüº°, À¯Åë ä³Îº°, ¿ëµµº°, Áö¿ªº°(2025-2033³â)
Immune Checkpoint Inhibitors Market Report by Type, Distribution Channel, Application, and Region 2025-2033
»óǰÄÚµå : 1635967
¸®¼­Ä¡»ç : IMARC Group
¹ßÇàÀÏ : 2025³â 01¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 124 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 2,999 £Ü 4,339,000
PDF & Excel (Single User License) help
PDF, Excel º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â 1ȸ °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 3,999 £Ü 5,786,000
PDF & Excel (5 User License) help
PDF, Excel º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 4,999 £Ü 7,233,000
PDF & Excel (Corporate License) help
PDF, Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¸é¿ª°ü¹®¾ïÁ¦Á¦ ½ÃÀåÀÇ ¼¼°è ½ÃÀå ±Ô¸ð´Â 2024³â 495¾ï ´Þ·¯¿¡ ´ÞÇßÀ¸¸ç, IMARC GroupÀº 2025³âºÎÅÍ 2033³â±îÁö 14.6%ÀÇ ¿¬Æò±Õ ¼ºÀå·ü(CAGR)·Î 2033³â¿¡´Â 1,686¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøÇϰí ÀÖ½À´Ï´Ù. ´Ù¾çÇÑ ¾ÏÀÇ À¯º´·ü Áõ°¡, È£Èí±âÁúȯÀÇ Áõ°¡, ¸ÂÃãÇü ÀǾàǰ¿¡ ´ëÇÑ ¼±È£µµ Áõ°¡ µîÀÌ ½ÃÀåÀ» ÁÖµµÇÏ´Â ÁÖ¿ä ¿äÀÎÀ¸·Î ²ÅÈü´Ï´Ù.

¸é¿ª°ü¹®¾ïÁ¦Á¦´Â T¼¼Æ÷³ª ¾Ï¼¼Æ÷ µî ¸é¿ª°è ¼¼Æ÷¿¡¼­ ¸¸µé¾îÁö´Â ƯÁ¤ ´Ü¹éÁúÀ» ¾ïÁ¦ÇÏ¿© ¾Ï Ä¡·á¿¡ ÀÌ¿ëµÇ´Â ¾à¹°ÀÔ´Ï´Ù. ´Üµ¶À¸·Î ¶Ç´Â È­Çпä¹ýÀ̳ª ¹æ»ç¼± Ä¡·á µî ´Ù¸¥ ¾Ï Ä¡·á¿Í ÇÔ²² »ç¿ëµÇ¾î Ä¡·á È¿°ú¸¦ ³ôÀÔ´Ï´Ù. ¸é¿ª°ü¹®¾ïÁ¦Á¦´Â Áúº´ÀÇ Áõ»óÀ» ¿ÏÈ­ÇÏ°í »ýÁ¸±â°£À» ¿¬ÀåÇÏ¿© ¾ÏȯÀÚÀÇ »îÀÇ ÁúÀ» ³ôÀÌ´Â µ¥ µµ¿òÀ» ÁÝ´Ï´Ù. ¸é¿ª°ü¹®¾ïÁ¦Á¦´Â ¸é¿ª°èÀÇ Æ¯Á¤ °æ·Î¸¦ Ç¥ÀûÀ¸·Î »ï±â ¶§¹®¿¡ º¸´Ù Ç¥ÀûÈ­µÈ ¾Ï Ä¡·á°¡ °¡´ÉÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ¾ïÁ¦Á¦´Â ±âÁ¸ È­Çпä¹ý¿¡ ºñÇØ ºÎÀÛ¿ëÀÌ Àû°í µ¶¼º ÇÁ·ÎÆÄÀÏÀÌ ³·¾Æ ȯÀÚÀÇ ³»¾à¼ºÀÌ ¿ì¼öÇÕ´Ï´Ù. ÇöÀç ¾Ï¼¼Æ÷ ³» ƯÁ¤ À¯ÀüÀÚ º¯À̸¦ ½Äº°ÇÒ ¼ö ÀÖ´Â Â÷¼¼´ë ¿°±â¼­¿­ ºÐ¼® ±â¼úÀÇ »ç¿ëÀÌ Áõ°¡Çϰí ÀÖÀ¸¸ç, ÀÌ´Â Àü ¼¼°èÀûÀ¸·Î ¸é¿ª°ü¹® ¾ïÁ¦Á¦¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

¸é¿ª°ü¹®¾ïÁ¦Á¦ ½ÃÀå µ¿Çâ:

Èæ»öÁ¾, °£¾Ï, ½ÅÀå¾Ï, À§¾Ï µî ´Ù¾çÇÑ ¾ÏÀÇ ¹ßº´·üÀÌ ±ÞÁõÇϰí ÀÖ´Â °ÍÀº Àü ¼¼°èÀûÀ¸·Î ¸é¿ª°ü¹®¾ïÁ¦Á¦¿¡ ´ëÇÑ ¼ö¿ä¸¦ Áõ°¡½ÃŰ´Â ÁÖ¿ä ¿äÀÎ Áß ÇϳªÀÔ´Ï´Ù. ¶ÇÇÑ, ÀÌ·¯ÇÑ ½É°¢ÇÑ ¾Ï¿¡ °É¸®±â ½¬¿î °í·ÉÈ­ Àα¸ÀÇ Áõ°¡¿Í ºñ¸¸ À¯º´·üÀÇ Áõ°¡´Â ½ÃÀå ¼ºÀåÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¾ËÄڿüº À½·á¿Í ´ã¹è ¼ÒºñÀÇ Áõ°¡·Î ÀÎÇØ È£Èí±âÁúȯÀÇ ¹ß»ý·üÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÀÌ´Â °Ç°­¿¡ ÇØ·Î¿î ½Ä½À°ü°ú ÁÂ½Ä »ýȰ ½À°üÀ¸·Î ÀÎÇØ üÁß°ú °ü·ÃµÈ °Ç°­ ¹®Á¦°¡ Áõ°¡ÇÔ¿¡ µû¶ó ½ÃÀå¿¡ ±àÁ¤ÀûÀÎ ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù. À̿ʹ º°µµ·Î ´Ù¾çÇÑ À¯Àü¼º ¹× »ýȰ½À°üº´ÀÇ ±ÞÁõ, ¾ÏÀÇ Á¶±â Áø´Ü ¹× Ä¡·áÀÇ ÀÌÁ¡¿¡ ´ëÇÑ °³ÀÎ ¹× ÀÇ·á Àü¹®°¡µéÀÇ ÀνÄÀÌ ³ô¾ÆÁö¸é¼­ ½ÃÀå ¼ºÀåÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Á¦¾à»çµéÀÇ ÀÓ»ó½ÃÇè È®´ë, ¸ÂÃãÇü ÀǾàǰ ¹× Â÷¼¼´ë ÀǾàǰ ¹× Á¦Á¦¿¡ ´ëÇÑ ¼±È£µµ°¡ ³ô¾ÆÁö¸é¼­ ½ÃÀå ¼ºÀåÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ÀÌ¿Í ´õºÒ¾î, Á¦Ç° Æ÷Æ®Æú¸®¿À¸¦ È®ÀåÇÏ°í °æÀï ¿ìÀ§¸¦ È®º¸Çϱâ À§ÇØ ÁÖ¿ä ±â¾÷µéÀÌ Àü·«Àû Á¦ÈÞ ¹× ½ÅÁ¦Ç° °³¹ß¿¡ ÁýÁßÇÏ´Â °æÇâÀÌ °­È­µÇ°í ÀÖ´Â Á¡µµ ½ÃÀå Àü¸ÁÀ» ¹à°Ô Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÀÇ·á ÀÎÇÁ¶ó¿Í Áø´Ü ±â¼úÀÇ ´ëÆøÀûÀÎ °³¼±ÀÌ ½ÃÀå ¼ºÀåÀ» °­È­ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

º» º¸°í¼­¿¡¼­ ´Ù·ç´Â ÁÖ¿ä Áú¹®

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹üÀ§¿Í Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ¼Ò°³

Á¦5Àå ¼¼°èÀÇ ¸é¿ª°ü¹®¾ïÁ¦Á¦ ½ÃÀå

Á¦6Àå ½ÃÀå ³»¿ª : À¯Çüº°

Á¦7Àå ½ÃÀå ³»¿ª : À¯Åë ä³Îº°

Á¦8Àå ½ÃÀå ³»¿ª : ¿ëµµº°

Á¦9Àå ½ÃÀå ³»¿ª : Áö¿ªº°

Á¦10Àå ÃËÁø¿äÀÎ, ¾ïÁ¦¿äÀÎ, ±âȸ

Á¦11Àå ¹ë·ùüÀÎ ºÐ¼®

Á¦12Àå Porter's Five Forces ºÐ¼®

Á¦13Àå °¡°Ý ºÐ¼®

Á¦14Àå °æÀï ±¸µµ

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The global immune checkpoint inhibitors market size reached USD 49.5 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 168.6 Billion by 2033, exhibiting a growth rate (CAGR) of 14.6% during 2025-2033. The rising prevalence of various cancers, increasing incidences of respiratory disorders, and the growing preference for personalized medicines represent some of the key factors driving the market.

Immune checkpoint inhibitors are drugs utilized for treating cancer by inhibiting specific proteins made by immune system cells, such as T cells and cancer cells. They are either used alone or in combination with other cancer treatments, such as chemotherapy and radiation therapy to enhance treatment outcomes. They aid in enhancing the quality of life for cancer patients by reducing the symptoms of the disease and extending their survival. Immune checkpoint inhibitors target specific pathways in the immune system, which enables a more targeted approach to cancer treatment. These inhibitors have a lower toxicity profile that leads to fewer side effects and better tolerance to patients as compared to traditional chemotherapy. At present, the rising use of next-generation sequencing technologies that enables the identification of specific genetic mutations in cancer cells is catalyzing the demand for immune checkpoint inhibitors across the globe.

Immune Checkpoint Inhibitors Market Trends:

The surging prevalence of various cancers among individuals, such as melanoma, liver, kidney, and gastric, represents one of the major factors driving the demand for immune checkpoint inhibitors around the world. Moreover, the increasing aging population, which is more prone to develop such severe cancers and the rising prevalence of obesity is favoring the market growth. In addition, there is an increase in the incidences of respiratory disorders on account of the rising consumption of alcoholic beverages and tobacco-based products. This, coupled with the growing numbers of weight-related health concerns on account of unhealthy eating habits and sedentary lifestyles, is influencing the market positively. Apart from this, the surging occurrence of various genetic and lifestyle diseases and the increasing awareness among individuals and healthcare professionals about the benefits of early diagnosis and treatment of cancer is propelling the growth of the market. Furthermore, the expanding number of clinical trials by pharmaceutical companies and the rising preference for personalized medicines and new generation drugs and formulations are propelling the growth of the market. Besides this, the growing focus of leading players on strategic collaborations and new product developments to expand their product portfolio and gain a competitive edge is creating a positive outlook for the market. Additionally, significant improvements in medical infrastructure and diagnostic technologies are anticipated to strengthen the growth of the market.

Key Market Segmentation:

Type Insights:

Distribution Channel Insights:

Application Insights:

Regional Insights:

Competitive Landscape:

Key Questions Answered in This Report

Table of Contents

1 Preface

2 Scope and Methodology

3 Executive Summary

4 Introduction

5 Global Immune Checkpoint Inhibitors Market

6 Market Breakup by Type

7 Market Breakup by Distribution Channel

8 Market Breakup by Application

9 Market Breakup by Region

10 Drivers, Restraints, and Opportunities

11 Value Chain Analysis

12 Porters Five Forces Analysis

13 Price Analysis

14 Competitive Landscape

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â